• SPX
  • $5,728.45
  • 0.5 %
  • $28.51
  • DJI
  • $42,013.41
  • 0 %
  • $1.81
  • N225
  • $38,635.62
  • 0.22 %
  • $83.56
  • FTSE
  • $8,293.07
  • 0.13 %
  • $10.55
  • IXIC
  • $18,029.60
  • 0.62 %
  • $111.12
Revolution Medicines, Inc. (RVMD) Stock Price, News & Analysis

Revolution Medicines, Inc. (RVMD) Stock Price, News & Analysis

Currency in USD Disclaimer

$47.15

$1.02

(2.21%)

Day's range
$46.5
Day's range
$47.67
50-day range
$40
Day's range
$47.67
  • Country: US
  • ISIN: US76155X1000
52 wk range
$15.44
Day's range
$48.61
  • CEO: Dr. Mark A. Goldsmith Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 23.22
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (RVMD)
  • Company Revolution Medicines, Inc.
  • Price $47.15
  • Changes Percentage (2.21%)
  • Change $1.02
  • Day Low $46.50
  • Day High $47.67
  • Year High $48.61

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/03/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $52.50
  • High Stock Price Target $61.00
  • Low Stock Price Target $43.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.84
  • Trailing P/E Ratio -10.51
  • Forward P/E Ratio -10.51
  • P/E Growth -10.51
  • Net Income $-436,367,000

Income Statement

Quarterly

Annual

Latest News of RVMD

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.